Camron Bryant | Profiles RNS

Camron D. Bryant, PhD

Assistant Professor

Boston University School of Medicine

Dept of Pharmacology & Experimental Therapeutics

PhD, University of California, Los Angeles

Websites

	Pharmacology & Experimental Therapeutics Faculty
	Laboratory of Addiction Genetics

ORCID : 0000-0003-4505-5809

Dr. Bryant is the Director of the Laboratory of Addiction Genetics. Dr. Bryant’s research program is focused on determining the genetic basis of behavioral and molecular traits relevant to substance dependence in mice. The ultimate goal is to improve our understanding of the neurobiological mechanisms of addiction and to translate these findings toward treatment and prevention strategies in humans. A current focus is to determine the genetic basis of the rewarding properties of opioids in mice by combining quantitative trait locus (QTL) analysis of behavior and gene expression in genetic reference populations that yield high resolution QTLs. This multi-pronged approach to gene mapping will accelerate the nomination of candidate genes for validation via direct gene targeting. A separate focus with regard to functional characterization of candidate genes is the dissection of the hypothesized opposing roles of casein kinase-1 (CK-1) isoforms in regulating dopaminergic signaling and the motivational properties of drugs of abuse. Last, Dr. Bryant has a longstanding interest in deciphering the neurobiological basis of the “placebo effect”, a phenomenon that has been hypothesized to be mediated by the reward expectation. He plans to develop and apply a forward genetic analysis toward Pavlovian conditioning mouse models across a variety of conditions that are notoriously sensitive to the placebo effect, including pain, anxiety, depression, and Parkinson’s Disease.

Director, Laboratory of Addiction Genetics
Boston University School of Medicine

2016 American College of Neuropsychopharmacology (ACNP): Elected Associate Member

2015 Boston University: Jack Spivack Excellence in Neurosciences Research Award

2014 International Behavioural and Neural Genetics Society (IBANGS): Young Scientist Award

2014 Winter Conference on Brain Research (WCBR): Junior Investigator Travel Fellowship

2013 World Congress of Psychiatric Genetics: Poster abstract selected for oral presentation

2013 International Behavioural and Neural Genetics Society (IBANGS): Outstanding Young Investigator Award for Junior Faculty

2012 International Behavioural and Neural Genetics Society (IBANGS): Travel Award

2011 American College of Neuropsychopharmacology (ACNP): Early Career Travel Award - Abstract selected for Breakout Session oral presentation

2011 NIDA: Travel Award for Miniconvention, “Frontiers in Addiction Research”

2011 International Behavioural and Neural Genetics Society (IBANGS): Travel Award

2011 International Narcotics Research Conference (INRC): Travel Award

2009 International Behavioural and Neural Genetics Society (IBANGS): Travel Award

2008 International Behavioural and Neural Genetics Society (IBANGS): Outstanding Young Investigator Award for Postdocs

2005 INRC: Travel Award

2002 INRC: Travel Award

2000 UCLA: Hatos Center for Neuropharmacology Training Fellowship

1999 UCLA: Achievement Rewards for College Scientists (ARCS) Scholarship

1998-1999 UIUC: Honors Program and thesis in the Department of Psychology

BU Sponsored Research
NIH RePORTER Sponsored Research

Genetic Basis of Chemotherapy-Induced Neuropathy in a Reduced Complexity Cross
02/07/2018 - 01/31/2022 (PI)
Virginia Commonwealth University NIH NCI
1R01CA221260-01A1

Big Data Computational Methods for Analysis of Drugs of Abuse
09/01/2017 - 06/30/2020 (PI)
The Leland Stanford Junior University NIH NIDA
5U01DA044399-02

Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in mice
07/01/2015 - 06/30/2020 (PI)
NIH/National Institute on Drug Abuse
5R01DA039168-04

Genetic basis of binge eating and its motivational components in a reduced complexity cross
09/15/2015 - 08/31/2018 (PI)
NIH/National Institute on Drug Abuse
5R21DA038738-02

Mapping G x E Interactions for Addiction Traits in a Reduced Complexity Cross
07/01/2014 - 06/30/2017 (PI)
NIH/National Institute on Drug Abuse
5R03DA038287-02

Bridging Genetic Variation with Behavior: Molecular and Functional Mechanisms.
05/01/2015 - 04/30/2017 (PI)
NIH/National Institute on Drug Abuse
3R00DA029635-05S2

Genetic Basis of Opioid Reward and Aversion in Mice
05/01/2013 - 04/30/2017 (PI)
NIH/National Institute on Drug Abuse
5R00DA029635-05S1

Yr	Title	Project-Sub Proj	Pubs
2018	Genetic basis of chemotherapy-induced neuropathy in a reduced complexity cross	1R01CA221260-01A1
2018	Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in mice	3R01DA039168-03S2	4
2018	Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in mice	5R01DA039168-04	4
2016	Genetic basis of binge eating and its motivational components in a reduced complexity cross	5R21DA038738-02	4
2016	Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in mice	5R01DA039168-02	4
2016	Genetic Basis of Opioid Reward and Aversion in Mice	3R00DA029635-05S2	3
2015	Genetic basis of binge eating and its motivational components in a reduced complexity cross	1R21DA038738-01A1	4
2015	Bridging genetic variation with behavior: Molecular and functional mechanisms of quantitative trait gene regulation of the stimulant and addictive properties of methamphetamine in mice	1R01DA039168-01A1	4
2015	Mapping G x E Interactions for Addiction Traits in a Reduced Complexity Cross	5R03DA038287-02	4
2015	Genetic Basis of Opioid Reward and Aversion in Mice	5R00DA029635-05	3

Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

Bryant CD, Bagdas D, Goldberg LR, Khalefa T, Reed ER, Kirkpatrick SL, Kelliher JC, Chen MM, Johnson WE, Mulligan MK, Imad Damaj M. C57BL/6 substrain differences in inflammatory and neuropathic nociception and genetic mapping of a major quantitative trait locus underlying acute thermal nociception. Mol Pain. 2019 Jan-Dec; 15:1744806918825046.View Related Profiles.
Bryant, Camron
Goldberg, Lisa
Johnson, William
PMID: 30632432.
Babbs RK, Kelliher JC, Scotellaro JL, Luttik KP, Mulligan MK, Bryant CD. Genetic differences in the behavioral organization of binge eating, conditioned food reward, and compulsive-like eating in C57BL/6J and DBA/2J strains. Physiol Behav. 2018 Dec 01; 197:51-66. PMID: 30261172.
Ruan QT, Yazdani N, Beierle JA, Hixson KM, Hokenson KE, Apicco DJ, Luttik KP, Zheng K, Maziuk BF, Ash PEA, Szumlinski KK, Russek SJ, Wolozin B, Bryant CD. Changes in neuronal immunofluorescence in the C- versus N-terminal domains of hnRNP H following D1 dopamine receptor activation. Neurosci Lett. 2018 09 25; 684:109-114.View Related Profiles.
Wolozin, Benjamin
Bryant, Camron
Apicco, Daniel
Beierle, Jacob
Hixson, Kathryn
Hokenson, Kristen
Yazdani, Neema
Ash, Peter
Russek, Shelley
PMID: 30003938.
Apicco DJ, Ash PEA, Maziuk B, LeBlang C, Medalla M, Al Abdullatif A, Ferragud A, Botelho E, Ballance HI, Dhawan U, Boudeau S, Cruz AL, Kashy D, Wong A, Goldberg LR, Yazdani N, Zhang C, Ung CY, Tripodis Y, Kanaan NM, Ikezu T, Cottone P, Leszyk J, Li H, Luebke J, Bryant CD, Wolozin B. Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci. 2018 Jan; 21(1):72-80.View Related Profiles.
Wolozin, Benjamin
Bryant, Camron
Apicco, Daniel
Luebke, Jennifer
Goldberg, Lisa
Medalla, Maria
Yazdani, Neema
Ash, Peter
Cottone, Pietro
Ikezu, Tsuneya
Tripodis, Yorghos
PMID: 29273772.
Goldberg LR, Kirkpatrick SL, Yazdani N, Luttik KP, Lacki OA, Keith Babbs R, Jenkins DF, Evan Johnson W, Bryant CD. Casein kinase 1-epsilon deletion increases mu opioid receptor-dependent behaviors and binge eating1. Genes Brain Behav. 2017 Sep; 16(7):725-738.View Related Profiles.
Bryant, Camron
Goldberg, Lisa
Yazdani, Neema
Johnson, William
PMID: 28594147.
Kirkpatrick SL, Goldberg LR, Yazdani N, Babbs RK, Wu J, Reed ER, Jenkins DF, Bolgioni AF, Landaverde KI, Luttik KP, Mitchell KS, Kumar V, Johnson WE, Mulligan MK, Cottone P, Bryant CD. Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating. Biol Psychiatry. 2017 May 01; 81(9):757-769.View Related Profiles.
Bolgioni-Smith, Amanda
Bryant, Camron
Mitchell, Karen
Goldberg, Lisa
Yazdani, Neema
Cottone, Pietro
Johnson, William
PMID: 27914629; DOI: 10.1016/j.biopsych.2016.10.021;.
Young EE, Bryant CD, Lee SE, Peng X, Cook B, Nair HK, Dreher KJ, Zhang X, Palmer AA, Chung JM, Mogil JS, Chesler EJ, Lariviere WR. Systems genetic and pharmacological analysis identifies candidate genes underlying mechanosensation in the von Frey test. Genes Brain Behav. 2016 Jul; 15(6):604-15. PMID: 27231153; PMCID: PMC4955286; DOI: 10.1111/gbb.12302;.
Yazdani N, Shen Y, Johnson WE, Bryant CD. Striatal transcriptome analysis of a congenic mouse line (chromosome 11: 50-60Mb) exhibiting reduced methamphetamine sensitivity. Genom Data. 2016 Jun; 8:77-80.View Related Profiles.
Bryant, Camron
Yazdani, Neema
Johnson, William
PMID: 27222804; DOI: 10.1016/j.gdata.2016.03.009;.
Bryant CD, Yazdani N. RNA-binding proteins, neural development and the addictions. Genes Brain Behav. 2016 Jan; 15(1):169-86.View Related Profiles.
Bryant, Camron
Yazdani, Neema
PMID: 26643147; PMCID: PMC4944654; DOI: 10.1111/gbb.12273;.
Yazdani N, Parker CC, Shen Y, Reed ER, Guido MA, Kole LA, Kirkpatrick SL, Lim JE, Sokoloff G, Cheng R, Johnson WE, Palmer AA, Bryant CD. Hnrnph1 Is A Quantitative Trait Gene for Methamphetamine Sensitivity. PLoS Genet. 2015 Dec; 11(12):e1005713.View Related Profiles.
Bryant, Camron
Yazdani, Neema
Johnson, William
PMID: 26658939; PMCID: PMC4675533; DOI: 10.1371/journal.pgen.1005713;.

Showing 10 of 31 results. Show More

Kirkpatrick SL, Bryant CD. Behavioral architecture of opioid reward and aversion in C57BL/6 substrains. Front Behav Neurosci. 2014; 8:450. PMID: 25628547; DOI: 10.3389/fnbeh.2014.00450;.
Zhou L, Bryant CD, Loudon A, Palmer AA, Vitaterna MH, Turek FW. The circadian clock gene Csnk1e regulates rapid eye movement sleep amount, and nonrapid eye movement sleep architecture in mice. Sleep. 2014; 37(4):785-93, 793A-793C. PMID: 24744456; PMCID: PMC3972422; DOI: 10.5665/sleep.3590;.
Zhou L, Bryant CD, Loudon A, Palmer AA, Holz Vilaterna M, Turek FW. The circadian clock gene Csnk1e regulates rapid eye movement sleep amount, and nonrapid eye movement sleep architecture in mice. Sleep. 2014; 37(4):785-93. PMID: 25025121.
Bryant CD, Guido MA, Kole LA, Cheng R. The heritability of oxycodone reward and concomitant phenotypes in a LG/J x SM/J F48 mouse advanced intercross line. Addiction Biology. 2014.
Bryant CD, Guido MA, Kole LA, Cheng R. The heritability of oxycodone reward and concomitant phenotypes in a LG/J?×?SM/J mouse advanced intercross line. Addict Biol. 2014 Jul; 19(4):552-61. PMID: 23231598; PMCID: PMC4300855; DOI: 10.1111/adb.12016;.
Bryant CD, Kole LA, Guido MA, Cheng R, Palmer AA. Methamphetamine-induced conditioned place preference in LG/J and SM/J mouse strains and an F45/F46 advanced intercross line. Front Genet. 2012; 3:126. PMID: 22798962; PMCID: PMC3393886; DOI: 10.3389/fgene.2012.00126;.
Bryant CD, Kole LA, Guido MA, Sokoloff G, Palmer AA. Congenic dissection of a major QTL for methamphetamine sensitivity implicates epistasis. Genes Brain Behav. 2012 Jul; 11(5):623-32. PMID: 22487465; PMCID: PMC3691852; DOI: 10.1111/j.1601-183X.2012.00795.x;.
Bryant CD. The blessings and curses of C57BL/6 substrains in mouse genetic studies. Ann N Y Acad Sci. 2011 Dec; 1245:31-3. PMID: 22211972; DOI: 10.1111/j.1749-6632.2011.06325.x;.
Bryant CD, Parker CC, Zhou L, Olker C, Chandrasekaran RY, Wager TT, Bolivar VJ, Loudon AS, Vitaterna MH, Turek FW, Palmer AA. Csnk1e is a genetic regulator of sensitivity to psychostimulants and opioids. Neuropsychopharmacology. 2012 Mar; 37(4):1026-35. PMID: 22089318; PMCID: PMC3280656; DOI: 10.1038/npp.2011.287;.
Hofford RS, Hodgson SR, Roberts KW, Bryant CD, Evans CJ, Eitan S. Extracellular signal-regulated kinase activation in the amygdala mediates elevated plus maze behavior during opioid withdrawal. Behav Pharmacol. 2009 Oct; 20(7):576-83. PMID: 19738463; DOI: 10.1097/FBP.0b013e32832ec57e;.
Bryant CD, Chang HP, Zhang J, Wiltshire T, Tarantino LM, Palmer AA. A major QTL on chromosome 11 influences psychostimulant and opioid sensitivity in mice. Genes Brain Behav. 2009 Nov; 8(8):795-805. PMID: 19694818; PMCID: PMC3697834; DOI: 10.1111/j.1601-183X.2009.00525.x;.
Bryant CD, Roberts KW, Culbertson CS, Le A, Evans CJ, Fanselow MS. Pavlovian conditioning of multiple opioid-like responses in mice. Drug Alcohol Depend. 2009 Jul 1; 103(1-2):74-83. PMID: 19419821; PMCID: PMC3085957; DOI: 10.1016/j.drugalcdep.2009.03.016;.
Bryant CD, Graham ME, Distler MG, Munoz MB, Li D, Vezina P, Sokoloff G, Palmer AA. A role for casein kinase 1 epsilon in the locomotor stimulant response to methamphetamine. Psychopharmacology (Berl). 2009 May; 203(4):703-11. PMID: 19050854; PMCID: PMC2729782; DOI: 10.1007/s00213-008-1417-z;.
Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS, Palmer AA, McRoberts JA. Behavioral differences among C57BL/6 substrains: implications for transgenic and knockout studies. J Neurogenet. 2008; 22(4):315-31. PMID: 19085272; PMCID: PMC3697827; DOI: 10.1080/01677060802357388;.
Gioiosa L, Chen X, Watkins R, Klanfer N, Bryant CD, Evans CJ, Arnold AP. Sex chromosome complement affects nociception in tests of acute and chronic exposure to morphine in mice. Horm Behav. 2008 Jan; 53(1):124-30. PMID: 17956759; PMCID: PMC2713052.
Bryant CD, Roberts KW, Byun JS, Fanselow MS, Evans CJ. Morphine analgesic tolerance in 129P3/J and 129S6/SvEv mice. Pharmacol Biochem Behav. 2006 Dec; 85(4):769-79. PMID: 17196637; PMCID: PMC1905890.
Bryant CD, Eitan S, Sinchak K, Fanselow MS, Evans CJ. NMDA receptor antagonism disrupts the development of morphine analgesic tolerance in male, but not female C57BL/6J mice. Am J Physiol Regul Integr Comp Physiol. 2006 Aug; 291(2):R315-26. PMID: 16601258.
Bryant CD, Zaki PA, Carroll FI, Evans CJ. Opioids and Addiction: Emerging pharmaceutical strategies for reducing reward and opponent processes. Clinical Neuroscience Research. 2005; (5):103-115.
Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003 Nov 12; 23(32):10331-7. PMID: 14614092.
Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, Keith D, Polakiewicz R, Evans CJ. Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci. 2003 Sep 10; 23(23):8360-9. PMID: 12967998.
Wilson SG, Bryant CD, Lariviere WR, Olsen MS, Giles BE, Chesler EJ, Mogil JS. The heritability of antinociception II: pharmacogenetic mediation of three over-the-counter analgesics in mice. J Pharmacol Exp Ther. 2003 May; 305(2):755-64. PMID: 12606637.

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 31 publications over 14 distinct years, with a maximum of 4 publications in 2016